Effective treatment of recurrent cholangiocarcinoma with Arotinib combined with Sintilimab injection： a case report and literature review

doi:10.3969/j.issn.1009-976X.2022.06.011

Abstract

Abstract: A patient with cholangiocarcinoma was found to have tumor recurrencemultiple intrahepatic metastasis and hilar lymph node metastasis 5 months after radical resection. She was treated with Arotinib combined with 9 courses of treatment with Sintilimab injection. Imaging examination showed that the tumor gradually shrank, necrotized and absorbed, and CA19-9 gradually decreases to normal value, achieve clinical cure. suggesting that arotinib combined with xindili monoclonal antibody in the treatment of cholangiocarcinoma can reduce the tumor load, prolong the survival time and improve the quality of life; However, its therapeutic mechanism and safety need to be further confirmed.

Key words: recurrent cholangiocarcinoma, arotinib, sintilimab injection, targeted therapy, immunotherapy

摘要： 本文报道1例胆管癌患者接受根治性切除术后5月即发现肿瘤肝内多发转移并肝门区淋巴结转移,予安罗替尼联合9疗程信迪利单抗免疫治疗,影像学检查提示肿瘤逐渐缩小、坏死并吸收,CA19-9逐渐下降至正常值,达到临床治愈。结果显示安罗替尼联合信迪利单抗在治疗胆管癌方面可降低肿瘤负荷,延长患者生存时间,提高生活质量;但其治疗机制及安全性有待进一步研究证实。

关键词: 复发性胆管癌, 安罗替尼, 信迪利单抗, 靶向治疗, 免疫治疗

CLC Number:

R735.8

WANG Zhong-hui, CHEN Gou-lin, SU Shu-ying. Effective treatment of recurrent cholangiocarcinoma with Arotinib combined with Sintilimab injection： a case report and literature review[J]. Lingnan Modern Clinics In Surgery, 2022, 22(06): 582-587.

王忠辉, 陈国林, 苏树英. 安罗替尼联合信迪利单抗治疗复发性胆管癌1例[J]. 岭南现代临床外科, 2022, 22(06): 582-587.

References

[1] Razumilava N, Gores GJ.Cholangiocarcinoma[J]. Lancet, 2014, 383(9935): 2168-2179.
[2] Rerknimitr R, Angsuwatcharakon P, Ratanachu-ek T, et al. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma[J]. J Gastroenterol Hepatol, 2013, 28(4): 593-607.
[3] Valle J, Wasan H, Palmer DH, et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281.
[4] Blechacz B.Cholangiocarcinoma: Current Knowledge and New Developments[J]. Gut Liver, 2017, 11(1): 13-26.
[5] Han B, Li K, Zhao Y, et al.Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)[J]. Br J Cancer, 2018, 118(5): 654-661.
[6] Zhang A, Liu B, Xu D, et al.Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report[J]. Medicine (Baltimore), 2019, 98(52): e18435.
[7] Song F, Hu B, Cheng JW, et al.Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma[J]. Cell Death Dis, 2020, 11(7): 573.
[8] Fan S, Ge Y, Liu J, et al.Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro[J]. J Clin Lab Anal, 2021, 35(10): e23986.
[9] Huang C, Wen Q, Chen J, et al.FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma[J]. Cancer Treat Res Commun, 2022, 31:100568.
[10] Zhang L, Mai W, Jiang W, et al.Sintilimab: A Promising Anti-Tumor PD-1 Antibody[J]. Front Oncol, 2020, 10:594558.
[11] Shi Y, Su H, Song Y, et al.Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial[J]. Lancet Haematol, 2019, 6(1): e12-e19.
[12] Gao S, Li N, Gao S, et al.Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC[J]. J Thorac Oncol, 2020, 15(5): 816-826.
[13] Ren Z, Xu J, Bai Y, et al.Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990.
[14] Liu J, Wang C, Cao L, et al.Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report[J]. Ann Palliat Med, 2020, 9(2): 497-503.
[15] Zhang J, Wu L, Liu J, et al.A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1inhibitor: a case report and literature review[J]. Immunotherapy, 2020, 12(8): 555-561.
[16] Zhang Z, Zhang W, Wang H, et al.Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report[J]. Front Immunol, 2021, 12:744571.
[17] Wang Z, Zeng T, Li Y, et al.PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature[J]. Front Immunol, 2021, 12:799822.